Stable Formulations of Botulinum Toxin in Hydrogels
The invention includes liquid formulations of botulinum toxin, including hydrogel formulations that are stable to storage in liquid form at standard refrigerator temperatures for at least 1-2 years and to storage at higher temperatures for at least 6 months. The invention also includes methods of treatment using such formulations for various therapeutic and cosmetic purposes.
1 . A stable liquid pharmaceutical botulinum toxin formulation for therapeutic use in humans, comprising a pharmaceutically acceptable buffer capable of providing a buffered pH range between about pH 5 and pH 6;
sodium chloride;
a therapeutic concentration of a purified botulinum toxin suitable for use in humans, wherein said purified botulinum toxin has not been dried or lyophilized; and
a hydrogel forming material;
wherein said formulation is stable as a liquid for at least one year at a temperature between about 0 and 10 degrees centigrade
2 . The formulation of claim 1 , wherein said temperature is about 5±3 degrees centrigrade.
3 . The formulation of claim 1 , wherein said temperature is about 4±2 degrees centigrade.
4 . The formulation of claim 1 , wherein said buffered pH range is about pH 5.6±0.2.
5 . The formulation of claim 1 , wherein said toxin formulation is stable in liquid form for at least two years.
6 . The formulation of claim 1 , wherein said buffer has a pK in the range of pH 4.5-6.5.
7 . The formulation of claim 6 , wherein said buffer is selected from the group consisting of phosphate buffer, phosphate-citrate buffer, and succinate buffer.
8 . The formulation of claim 1 , wherein said botulinum toxin is a botulinum toxin serotype selected from the group consisting of serotypes A, B, C1, C2, D, E, F and G.
9 . The formulation of claim 8 , wherein said botulinum toxin is botulinum toxin Type B present at a concentration in the range of about 100-20,000 U/ml.
10 . The formulation of claim 9 , wherein said botulinum toxin Type B is present in a high molecular weight complex of about 700 kilodaltons (kD).
11 . The formulation of claim 9 , wherein said botulinum toxin Type B is present at a concentration between about 1000-5000 U/ml.
12 . The formulation of claim 8 , wherein said botulinum toxin is botulinum toxin Type A, present at a concentration in the range of about 20-2000 U/ml.
13 . The formulation of claim 12 , wherein said botulinum toxin Type A is present at a concentration in the range of about 100-1000 U/ml.
14 . The formulation of claim 1 , which further includes an excipient protein.
15 . The formulation of claim 1 , wherein said excipient protein is selected from the group consisting of serum albumin, recombinant human serum albumin, and gelatin.
16 . The formulation of claim 1 wherein said hydrogel forming material comprises poloxamers, hyaluronan polymer, glycosaminoglycan polymer, sulfate polymer, polysaccharides, poly(ethyleneglycol), poly(lactic acid), poly(hydroxyethyl-methacrylate), poly(methylmethacrylate), proteins, or a combination thereof.
17 . The formulation of claim 16 , wherein said hydrogel forming material comprises a polysaccharide selected from hyaluronic acid, chitosan, chondroitin sulfate, alginate, carboxymethylcellulose, or a combination thereof.
18 . The formulation of claim 16 , wherein said hydrogel forming material comprises a protein selected from elastin, collagen, or a combination thereof. The formulation of claim 1 , wherein said botulinum type B is present at a concentration of about 5,000±1000 U/ml in said formulation.
19 . The formulation of claim 1 , wherein said toxin formulation is stable as a liquid for at least about 6 months at a temperature between about 10 and 30 degrees centigrade.
20 . The formulation of claim 19 , wherein said temperature is about 25° C.
21 . The formulation of claim 19 , wherein said buffered pH range is about pH 5.6±0.2.
22 . The formulation of claim 19 , wherein said buffer has a pK in the range of pH 4.5-6.5.
23 . The formulation of claim 22 , wherein said buffer is selected from the group consisting of phosphate buffer, phosphate-citrate buffer, and succinate buffer.
24 . The formulation of claim 19 , wherein said botulinum toxin is a botulinum toxin serotype selected from the group consisting of serotypes A, B, C1, C2, D, E, F and G.
25 . The formulation of claim 24 , wherein said botulinum toxin is botulinum toxin Type B present at a concentration of about 100-20,000 U/ml.
26 . The formulation of claim 25 , wherein said botulinum toxin Type B is present in a high molecular weight complex of about 700 kD.
27 . The formulation of claim 25 , wherein said botulinum toxin Type B is present at a concentration in the range of about 1000-5000 U/ml.
28 . The formulation of claim 24 , wherein said botulinum toxin is botulinum toxin Type A, present at a concentration in the range of about 20-2000 U/ml.
29 . The formulation of claim 19 , which further includes an excipient protein.
30 . The formulation of claim 30 , wherein said excipient protein is selected from the group consisting of serum albumin, human serum albumin, and gelatin.
31 . A method of treating a patient in need of inhibition of cholinergic input to a selected muscle, muscle group, gland or organ, comprising administering to the selected muscle, muscle group, gland or organ of the patient a pharmaceutically effective dose of a stable hydrogel botulinum toxin formulation according to claim 1 .